Diversified Consumer Services
Company Overview of University of Rochester
University of Rochester is an educational institution offering degree programs at the bachelors, masters, and doctoral level. The schools of the university include William E. Simon Graduate School of Business Administration; Margaret Warner Graduate School of Education and Human Development; School of Medicine and Dentistry; School of Nursing; Strong Memorial Hospital; Golisano Children's Hospital; Eastman Dental Center; Laboratory for Laser Energetic; and Center for Optoelectronics and Imaging. University of Rochester was established in 1850 and is based in Rochester, New York. The university has endowment assets worth $1298 million.
601 Elmwood Ave
Rochester, NY 14642-0001
Founded in 1851
Key Executives for University of Rochester
Professor of Finance and Statistics
Compensation as of Fiscal Year 2015.
University of Rochester Key Developments
University of Rochester Appoints Elizabeth Stauderman as Vice President for Communications to Replace Bill Murphy
May 29 15
Elizabeth Stauderman, who has been chief communications officer at Yale University, will be the new vice president for communications at the University of Rochester. Stauderman, who will begin full time at UR in August, will fill the vacancy left by Bill Murphy, who is retiring. He has served as chief spokesman for the university since 2006. Stauderman, 53, has spent most of her professional career at Yale, after graduating from that university with a bachelor's in history in 1983. Previously, Stauderman held such positions at Yale as deputy chief communications officer, associate dean for communications and strategy at the Yale School of Management and director of public affairs for Yale Law School.
Panther Biotechnology, Inc. Enters into Global License Agreement with University of Rochester
Apr 17 15
Panther Biotechnology Inc. announced that it has entered into an exclusive global license agreement with the University of Rochester.
Under the terms of the agreement, Panther has licensed from the University of Rochester, the rights to develop and commercialize a first in class new chemical entity with demonstrated powerful anti-leukemia activity. The licensed compound, called TDZD-8, is a small molecule engineered to kill leukemic stem cells. TDZD-8 has demonstrated broad and selective in vitro activity against many different types of leukemia. In addition, TDZD-8 has no significant toxicity in normal hematopoietic stem cells. TDZD-8 is a kinase inhibitor and induces oxidative stress, causing its striking ability to induce the leukemia cells to die after less than 2 hours of exposure to the drug.
University of Rochester Presents at AVCJ Private Equity & Venture Forum - Australia & New Zealand 2015, Mar-04-2015
Dec 2 14
University of Rochester Presents at AVCJ Private Equity & Venture Forum - Australia & New Zealand 2015, Mar-04-2015 . Venue: The Westin Sydney, No.1 Martin Place, Sydney, NSW 2000, Australia.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|